IRCT20181026041471N1招募中3 期
Evaluating the effect of dapagliflozin on preventing contrast-associated acute kidney injury in patients with acute coronary syndrome undergoing angiography (DARIUS); a multicenter, randomized, double-blind, placebo-controlled clinical trial
Rajaie Cardiovascular Medical and Research Institute0 个研究点目标入组 1,500 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 1,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Patients over 18 years old hospitalized with acute coronary syndrome (i.e. ST elevation or NST elevation myocardial infarction or unstable angina) diagnosis and candidates for coronary angiography or angioplasty
- •Signed informed consent to participate in the study
排除标准
- •Patients previously treated with SGLT2 inhibitor drugs
- •Creatinine clearance less than 25 ml/min
- •Chronic liver disease and cirrhosis (Child-Pugh C)
- •Drug allergy or history of severe hypersensitivity to dapagliflozin or its components
- •Non-consent to participate in the study
- •History of recurrent urinary tract infections
- •History of ketoacidosis
- •Pregnancy or breastfeeding
- •Type 1 diabetes mellitus
研究者
相似试验
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionEUCTR2016-003897-41-PLAstraZeneca AB4,500
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionMedDRA version: 20.0 Level: PT Classification code 10007558 Term: Cardiac failure chronic System Organ Class: 10007541 - Cardiac disordersEUCTR2016-003897-41-DKAstraZeneca AB4,500
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.Chronic Heart Failure (HF) with Reduced Ejection FractionEUCTR2016-003897-41-BGAstraZeneca AB4,500
进行中（未招募）
1 期
Study to evaluate if dapagliflozin treatment is effective in patients with heart failure by reducing the number of hospitalizations and urgent visits due to heart failure, and by reducing the risk of death.EUCTR2016-003897-41-SEAstraZeneca AB4,500
已完成
3 期
DAPA-HFChronic Heart Failure With Reduced Ejection Fraction (HFrEF)JPRN-jRCT2080223469AstraZeneca KK330